Free Newsletter
Scientists criticize $1.5 cancer atlas project
A growing number of prominent scientists are raising serious criticisms about the government's $1.5 billion Cancer Genome Atlas, calling it a waste of money at a time when federal funding for science is facing a critical challenge. The key criticism is that the atlas intends to catalog mutations related to primary tumors. But the researchers say that primary tumors aren't the chief threat. A more serious threat are the malignant cells that cause metastases, a rapid spread of cancer to other organs. The atlas may miss these cells, while identifying scores of mutations that are innocuous, critics maintain. Mutations in primary tumors may not be optimal drug targets and the mutations they track largely irrelevant. Noted UCLA cancer researcher Dennis Slamon says that even if the atlas identifies mutations, researchers will still be left with the hard work of determining if they cause cancer.
- read the report from MSNBC
Related Article:
Major research grants headed to sequencing centers. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment